CADUET

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, France, Hong Kong SAR China, Japan, Lithuania, Malta, Mexico, Nigeria, Romania, Singapore, South Africa, Spain, Tunisia, Turkey.

Active ingredients

The drug CADUET contains a combination of these active pharmaceutical ingredients (APIs):

1	Amlodipine UNII 864V2Q084H - AMLODIPINE BESYLATE
	Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.
	Read more about Amlodipine
2	Atorvastatin UNII 48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE
	Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.
	Read more about Atorvastatin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CADUET Film-coated tablet	MPI, US: SPL/PLR	Marketing Authorisation Holder

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10BX03	Atorvastatin and amlodipine	C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BX Lipid modifying agents in combination with other drugs
Discover more medicines within C10BX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	9051J, 9052K, 9053L, 9054M, 9055N, 9056P
CA	Health Products and Food Branch	02273233, 02273241, 02273268, 02273276, 02273284, 02273292, 02273306, 02273314
ES	Centro de información online de medicamentos de la AEMPS	67325, 67326
FR	Base de données publique des médicaments	60386460, 60772273, 63123849, 65364681, 66709963
HK	Department of Health Drug Office	53714, 53715, 53716, 53717, 53718, 53719, 53720, 53721
HR	Agencija za lijekove i medicinske proizvode	HR-H-444337926, HR-H-732959683
JP	医薬品医療機器総合機構	2190101F1020, 2190102F1025, 2190103F1020, 2190104F1024
LT	Valstybinė vaistų kontrolės tarnyba	1005137, 1005138, 1021103, 1021104, 1021105, 1021106, 1021107, 1021108, 1021109, 1021110, 1021111, 1021112, 1021113, 1021114, 1021115, 1021116, 1021117, 1021118, 1021119, 1021120, 1021121, 1021122, 1021123, 1021124, 1021125, 1021126
MT	Medicines Authority	MA1396/00201, MA1396/00202
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	204M2004
NG	Registered Drug Product Database	04-8468
Switch country to Nigeria in order to find specific presentations of CADUET
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67262001, W67263001
SG	Health Sciences Authority	13055P, 13056P, 13057P, 13059P, 13060P, 13061P
TN	Direction de la Pharmacie et du Médicament	26323011, 26323012
TR	İlaç ve Tıbbi Cihaz Kurumu	8699532095633, 8699532095640, 8699532095671, 8699532095688
US	FDA, National Drug Code	0069-2150, 0069-2160, 0069-2170, 0069-2180, 0069-2190, 0069-2250, 0069-2260, 0069-2270
ZA	Health Products Regulatory Authority	A39/7.0/0326, A39/7.0/0327, A39/7.0/0328, A39/7.0/0329, A39/7.0/0330, A39/7.0/0331, A39/7.0/0332, A39/7.0/0333